$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000121723420000192 Filed on October 29, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$58.64M	$53.37M	$33.81M
YoY Change	63.7%	57.85%	59.61%
Cost Of Revenue	$18.89M	$16.82M	$11.49M
YoY Change	48.51%	46.34%	29.33%
Gross Profit	$39.76M	$36.55M	$22.32M
YoY Change	72.05%	63.78%	81.48%
Gross Profit Margin	67.8%	68.49%	66.01%
Selling, General & Admin	$29.50M	$26.99M	$20.54M
YoY Change	49.75%	31.37%	84.28%
% of Gross Profit	74.2%	73.84%	92.05%
Research & Development	$13.33M	$12.47M	$8.521M
YoY Change	48.94%	46.39%	120.29%
% of Gross Profit	33.53%	34.13%	38.18%
Depreciation & Amortization	$1.960M	$1.800M	$1.460M
YoY Change	16.67%	23.29%	44.55%
% of Gross Profit	4.93%	4.92%	6.54%
Operating Expenses	$42.82M	$56.28M	$40.56M
YoY Change	49.46%	38.75%	170.1%
Operating Profit	-$3.060M	-$2.907M	-$6.747M
YoY Change	-44.77%	-56.91%	148.14%
Interest Expense	-$380.0K	$29.00K	$37.00K
YoY Change	-159.38%	-21.62%	-109.07%
% of Operating Profit
Other Income/Expense, Net	-$240.0K	-$146.0K	$3.985M
YoY Change	200.0%	-103.66%	-122.72%
Pretax Income	-$3.690M	-$3.053M	-$2.762M
YoY Change	-25.9%	10.54%	-86.37%
Income Tax	-$170.0K	-$200.0K	-$900.0K
% Of Pretax Income
Net Earnings	-$3.520M	-$2.818M	-$1.813M
YoY Change	-26.31%	55.43%	-90.92%
Net Earnings / Revenue	-6.0%	-5.28%	-5.36%
Basic Earnings Per Share		-$0.06	-$0.04
Diluted Earnings Per Share	-$71.33K	-$0.06	-$0.04
COMMON SHARES
Basic Shares Outstanding	49.26M shares	49.01M shares	42.39M shares
Diluted Shares Outstanding		49.01M shares	42.39M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$224.7M	$213.8M	$40.90M
YoY Change	488.22%	422.74%	56.11%
Cash & Equivalents	$134.7M	$213.8M	$40.90M
Short-Term Investments	$90.00M
Other Short-Term Assets	$3.800M	$4.300M	$2.100M
YoY Change	5.56%	104.76%	40.0%
Inventory	$10.01M	$9.906M	$5.902M
Prepaid Expenses
Receivables	$34.62M	$30.61M	$19.17M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$273.1M	$258.7M	$68.12M
YoY Change	279.71%	279.69%	62.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.70M	$10.14M	$3.656M
YoY Change	141.63%	177.46%	20.98%
Goodwill	$23.86M	$23.90M	$23.78M
YoY Change	0.0%	0.52%	98.06%
Intangibles	$44.36M	$43.83M	$45.78M
YoY Change	-2.6%	-4.26%	33.53%
Long-Term Investments
YoY Change
Other Assets	$1.000M	$1.000M	$1.000M
YoY Change	0.0%	0.0%	400.0%
Total Long-Term Assets	$95.41M	$94.89M	$76.71M
YoY Change	19.55%	23.71%	55.1%
TOTAL ASSETS
Total Short-Term Assets	$273.1M	$258.7M	$68.12M
Total Long-Term Assets	$95.41M	$94.89M	$76.71M
Total Assets	$368.5M	$353.6M	$144.8M
YoY Change	142.86%	144.11%	58.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.653M	$9.519M	$5.691M
YoY Change	75.32%	67.26%	110.78%
Accrued Expenses	$25.60M	$19.70M	$16.00M
YoY Change	36.17%	23.13%	66.67%
Deferred Revenue	$3.530M	$3.213M	$3.190M
YoY Change	-4.23%	0.72%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$100.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$69.22M	$62.42M	$30.97M
YoY Change	98.74%	101.55%	96.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$100.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$240.0K	$747.0K	$2.263M
YoY Change	-86.29%	-66.99%	49.08%
Total Long-Term Liabilities	$240.0K	$747.0K	$2.263M
YoY Change	-86.29%	-66.99%	49.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$69.22M	$62.42M	$30.97M
Total Long-Term Liabilities	$240.0K	$747.0K	$2.263M
Total Liabilities	$90.83M	$84.91M	$47.29M
YoY Change	72.24%	79.55%	0.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$352.5M	-$349.0M	-$329.0M
YoY Change	5.61%	6.08%	6.79%
Common Stock	$632.3M	$622.0M	$432.5M
YoY Change	44.36%	43.81%	21.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$277.7M	$268.6M	$97.54M
YoY Change
Total Liabilities & Shareholders Equity	$368.5M	$353.6M	$144.8M
YoY Change	142.86%	144.11%	58.38%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$3.520M	-$2.818M	-$1.813M
YoY Change	-26.31%	55.43%	-90.92%
Depreciation, Depletion And Amortization	$1.960M	$1.800M	$1.460M
YoY Change	16.67%	23.29%	44.55%
Cash From Operating Activities	$7.180M	$5.210M	$600.0K
YoY Change	-764.81%	768.33%	53.85%
INVESTING ACTIVITIES
Capital Expenditures	-$440.0K	-$4.240M	-$430.0K
YoY Change	-64.23%	886.05%	-30.65%
Acquisitions
YoY Change
Other Investing Activities	-$90.03M	$0.00	-$3.080M
YoY Change	81745.45%	-100.0%
Cash From Investing Activities	-$90.47M	-$4.240M	-$3.520M
YoY Change	6651.49%	20.45%	477.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.960M	1.230M	750.0K
YoY Change	4850.0%	64.0%	-92.65%
NET CHANGE
Cash From Operating Activities	7.180M	5.210M	600.0K
Cash From Investing Activities	-90.47M	-4.240M	-3.520M
Cash From Financing Activities	3.960M	1.230M	750.0K
Net Change In Cash	-79.33M	2.200M	-2.170M
YoY Change	3290.17%	-201.38%	-121.74%
FREE CASH FLOW
Cash From Operating Activities	$7.180M	$5.210M	$600.0K
Capital Expenditures	-$440.0K	-$4.240M	-$430.0K
Free Cash Flow	$7.620M	$9.450M	$1.030M
YoY Change	4980.0%	817.48%	1.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P8Y2M
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36536
	dei	Entity Registrant Name EntityRegistrantName	CAREDX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3316839
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Tower Place
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	415
	dei	Local Phone Number LocalPhoneNumber	287-2300
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	CDNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49257216	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	213798000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38223000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30610000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24057000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	9906000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6014000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4345000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3628000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	258659000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5506000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13791000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	71922000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10144000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4430000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15802000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4730000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43830000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45541000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	23857000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	23857000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	260000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	256000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1000000	USD
CY2020Q3	us-gaap	Assets Assets	353552000	USD
CY2019Q4	us-gaap	Assets Assets	151736000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9519000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12484000	USD
CY2020Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18617000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16838000	USD
CY2020Q3	cdna	Contract With Customer Liability Current Advance Payment Cares Act ContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	20496000	USD
CY2019Q4	cdna	Contract With Customer Liability Current Advance Payment Cares Act ContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	0	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	62423000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34828000	USD
CY2020Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1187000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1973000	USD
CY2020Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	532000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6607000	USD
CY2020Q3	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	3480000	USD
CY2019Q4	cdna	Deferred Payments For Intangible Assets Noncurrent DeferredPaymentsForIntangibleAssetsNoncurrent	5207000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16539000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2370000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	747000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1751000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	84908000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	52736000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49132348	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49132348	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42498430	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42498430	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	621961000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	437976000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4352000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5205000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-349012000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333813000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	268644000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	99000000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353552000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151736000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53369000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33811000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	133550000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91247000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12474000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8521000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35616000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21765000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13870000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11058000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37727000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28627000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13117000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9485000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35436000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27103000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	56276000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	40558000	USD
	us-gaap	Operating Expenses OperatingExpenses	153011000	USD
	us-gaap	Operating Expenses OperatingExpenses	110234000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2907000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6747000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19461000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18987000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	29000	USD
CY2019Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	37000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	146000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	679000	USD
CY2020Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	79000	USD
CY2019Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4346000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-990000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-14000	USD
CY2020Q3	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	0	USD
CY2019Q3	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	0	USD
	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	4813000	USD
	cdna	Relief Fund Provider Cares Act ReliefFundProviderCARESAct	0	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-254000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-398000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-572000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-644000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-146000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3985000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3397000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3053000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2762000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16064000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18966000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-235000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-949000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-865000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1775000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-2818000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-1813000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15199000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17191000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49010680	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42393550	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45526810	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42048647	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49010680	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42393550	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45526810	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42048647	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-2818000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-1813000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15199000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17191000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	962000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-863000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	853000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1656000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1856000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2676000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14346000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18847000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	99000000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	699000	USD
CY2020Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1507000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	66000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	155000	USD
CY2020Q1	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	6299000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4200000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1705000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5823000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	101384000	USD
CY2020Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-2030000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	58000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1962000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6320000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1596000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6558000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	260767000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	694000	USD
CY2020Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-466000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	96000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1647000	USD
CY2020Q3	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	1109000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6653000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	962000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-2818000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	268644000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	95928000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	341000	USD
CY2019Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-2378000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1365000	USD
CY2019Q1	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	2569000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6001000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-724000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-7531000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	95622000	USD
CY2019Q2	cdna	Change In Estimated Offering Costs ChangeInEstimatedOfferingCosts	50000	USD
CY2019Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1597000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	52000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1405000	USD
CY2019Q2	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	612000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4938000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-69000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-7847000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	93166000	USD
CY2019Q3	cdna	Adjustments To Additional Paid In Capital Business Combination Equity Component Of Contingent Consideration AdjustmentsToAdditionalPaidInCapitalBusinessCombinationEquityComponentOfContingentConsideration	222000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	418000	USD
CY2019Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-29000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	54000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	476000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5912000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-863000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-1813000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	97543000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15199000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17191000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17424000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17010000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-990000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-14000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5052000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3840000	USD
	cdna	Loss On Write Off Of Fixed Assets LossOnWriteOffOfFixedAssets	0	USD
	cdna	Loss On Write Off Of Fixed Assets LossOnWriteOffOfFixedAssets	160000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1896000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1129000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	301000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5359000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7816000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3608000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1327000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	681000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-566000	USD
	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1096000	USD
	cdna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1436000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3831000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1003000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	1501000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	1038000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1581000	USD
	cdna	Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	0	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	879000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2478000	USD
	cdna	Increase Decrease In Contract With Customer Liability Current Advance Payment Cares Act IncreaseDecreaseInContractWithCustomerLiabilityCurrentAdvancePaymentCARESAct	-20496000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1154000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26250000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1686000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	18119000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3250000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1148000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6670000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	970000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9920000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21237000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1082000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	760000	USD
	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	4003000	USD
	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	4004000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	343000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	105000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3764000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3245000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	136000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	128000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	192000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	159185000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-214000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-493000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	175579000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23630000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64808000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	214058000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41178000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	213798000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38223000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	260000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	256000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	214058000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38479000	USD
CY2018Q1	cdna	Number Of Renal Transplant Patients NumberOfRenalTransplantPatients	1600	patient
CY2020Q3	cdna	Number Of Transplant Centers Offering Remo Tra C NumberOfTransplantCentersOfferingRemoTraC	150	center
CY2020Q3	cdna	Number Of Patients Enrolled In Remo Tra C NumberOfPatientsEnrolledInRemoTraC	5000	patient
CY2020Q3	cdna	Number Of Mobile Phlebotomists NumberOfMobilePhlebotomists	10000	phlebotomist
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-349000000.0	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	213800000	USD
CY2020Q2	cdna	Cares Act Centers For Medicare And Medicaid Services Proceeds From Advance Payment CARESActCentersForMedicareAndMedicaidServicesProceedsFromAdvancePayment	20500000	USD
CY2020Q2	cdna	Cares Act Medicare Fee For Service Reimbursements Proceeds Initial Tranche CARESActMedicareFeeForServiceReimbursementsProceedsInitialTranche	4800000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Presenta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">tion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of certain prior period amounts within the previously disclosed cost of revenue have been changed, including separate line items for presentation of cost of testing services, cost of product and cost of digital and other. These changes in presentation had no effect on the reported results of operations.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of digital revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2020 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, approximately 58% and 54%, respectively, of total revenue was derived from Medicare. For the nine months ended September 30, 2020 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, approximately 56% and 39%, respectively, of total revenue was derived from Medicare. No other payers or customers represented more than 10% of total revenue for these periods.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, approximately 28% and 36%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable on either September 30, 2020 or December 31, 2019.</span></div>
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-2818000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-1813000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15199000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17191000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49010680	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42393550	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45526810	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42048647	shares
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5009115	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5009115	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4576094	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4576094	shares
CY2019Q2	us-gaap	Goodwill Goodwill	10200000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	23900000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	59816000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14264000	USD
CY2020Q3	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2972000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	57713000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42580000	USD
CY2020Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	61066000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14264000	USD
CY2020Q3	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2972000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43830000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10719000	USD
CY2019Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	3556000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43438000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	59816000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10719000	USD
CY2019Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	3556000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	45541000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1226000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4671000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4653000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4653000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4653000	USD
CY2020Q3	cdna	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	22724000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42580000	USD
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1550000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1236000	USD
CY2020Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2520000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1189000	USD
CY2020Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	5836000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3589000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	9906000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6014000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3213000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3686000	USD
CY2020Q3	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	5351000	USD
CY2019Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	3068000	USD
CY2020Q3	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2042000	USD
CY2019Q4	cdna	Deferred Payments For Intangible Assets DeferredPaymentsForIntangibleAssets	2098000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1872000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3017000	USD
CY2020Q3	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	368000	USD
CY2019Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	835000	USD
CY2020Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	996000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	547000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1730000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	810000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1502000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	766000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1543000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2011000	USD
CY2020Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	18617000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16838000	USD
CY2020Q2	cdna	Cares Act Centers For Medicare And Medicaid Services Proceeds From Advance Payment CARESActCentersForMedicareAndMedicaidServicesProceedsFromAdvancePayment	20500000	USD
CY2020Q1	cdna	Operating Lease Right Of Use Asset Increase OperatingLeaseRightOfUseAssetIncrease	13000000.0	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15800000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1900000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16500000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1120000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	453000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3353000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1358000	USD
CY2020Q3	cdna	Finance Lease Cost FinanceLeaseCost	51000	USD
CY2019Q3	cdna	Finance Lease Cost FinanceLeaseCost	54000	USD
	cdna	Finance Lease Cost FinanceLeaseCost	155000	USD
	cdna	Finance Lease Cost FinanceLeaseCost	164000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	1171000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	507000	USD
	us-gaap	Lease Cost LeaseCost	3508000	USD
	us-gaap	Lease Cost LeaseCost	1522000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y5M12D
CY2020Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M9D
CY2020Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.060
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3600000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	52000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	857000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	71000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3530000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3967000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2811000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2909000	USD
CY2020Q3	cdna	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	USD
CY2020Q3	cdna	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	13267000	USD
CY2020Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	123000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	27341000	USD
CY2014Q2	cdna	Number Of Milestone Payments NumberOfMilestonePayments	6	milestone_payment
CY2019Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2020Q3	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	USD
CY2020Q3	cdna	Purchase Of Common Stock Warrants Exercised PurchaseOfCommonStockWarrantsExercised	35000	shares
CY2020Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	100000	USD
	cdna	Purchase Of Common Stock Warrants Exercised PurchaseOfCommonStockWarrantsExercised	307000	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	300000	USD
CY2020Q3	cdna	Number Of Warrants Exercised Cashless Basis NumberOfWarrantsExercisedCashlessBasis	0	shares
	cdna	Number Of Warrants Exercised Cashless Basis NumberOfWarrantsExercisedCashlessBasis	34000	shares
	cdna	Purchase Of Common Stock Warrants Exercised PurchaseOfCommonStockWarrantsExercised	94000	shares
	cdna	Stock Issued During Period Shares Cashless Warrants Exercises In Period StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod	24000	shares
CY2019Q3	cdna	Purchase Of Common Stock Warrants Exercised PurchaseOfCommonStockWarrantsExercised	0	shares
CY2019Q3	cdna	Number Of Warrants Exercised Cashless Basis NumberOfWarrantsExercisedCashlessBasis	111400	shares
CY2019Q3	cdna	Stock Issued During Period Shares Cashless Warrants Exercises In Period StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod	9000	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	100000	USD
	cdna	Number Of Warrants Exercised Cashless Basis NumberOfWarrantsExercisedCashlessBasis	207400000	shares
	cdna	Stock Issued During Period Shares Cashless Warrants Exercises In Period StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod	49000000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	504775	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2609848	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1699549	shares
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices	8814	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1108504	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1034939	shares
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Including Prior Period Shares Adjustment ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossIncludingPriorPeriodSharesAdjustment	1034939	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	28.30
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	406406	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.18
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans	159749	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	160275	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	133196	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	133196	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	25.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	22912	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	22912	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	16.97
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	528199	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3082273	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.01
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4000000.0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8000000.0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2300000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14300000	USD
CY2020Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	1137000	shares
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	14.27
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y8M26D
CY2020Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	26916000000	USD
CY2020Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	1797000	shares
CY2020Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	24.92
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y10M24D
CY2020Q3	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	23391000000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2934000	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	50307000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1800000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6748000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5964000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17424000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17010000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-900000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-900000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-900000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53369000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33811000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	133550000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91247000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10144000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4430000	USD

Files In Submission

Name	View Source	Status
0001217234-20-000192-index-headers.html	Edgar Link	pending
0001217234-20-000192-index.html	Edgar Link	pending
0001217234-20-000192.txt	Edgar Link	pending
0001217234-20-000192-xbrl.zip	Edgar Link	pending
cdna-20200930.htm	Edgar Link	pending
cdna-20200930.xsd	Edgar Link	pending
cdna-20200930x10qxexx311.htm	Edgar Link	pending
cdna-20200930x10qxexx312.htm	Edgar Link	pending
cdna-20200930x10qxexx321.htm	Edgar Link	pending
cdna-20200930_cal.xml	Edgar Link	unprocessable
cdna-20200930_def.xml	Edgar Link	unprocessable
cdna-20200930_htm.xml	Edgar Link	completed
cdna-20200930_lab.xml	Edgar Link	unprocessable
cdna-20200930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2020 Q4 Form 10-Q Financial Statement

#000121723420000192 Filed on October 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2020 Q4 Form 10-Q Financial Statement

#000121723420000192 Filed on October 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna